20 November 2026
On 19 November 2026, Novartis shared an update with its investors and with the FSHD community about delpacibart braxlosiran (del-brax), an experimental treatment designed to reduce the damaging activity of DUX4 in FSHD. Here’s what this news means for the FSHD community.
What is the main news?
Novartis has discussed the Phase 3 trial design with the US Food and Drug Administration (FDA), sharing results from the trial to date. Following this meeting, Novartis confirmed with the FSHD community that the Phase 3 study design of FORTITUDE-3, the del-brax clinical trial, is aligned with the FDA, and that results are expected in 2029.
Essentially, as the FDA is looking for longer-term clinical data to better understand the potential effects of del-brax on FSHD in the body, Novartis is extending the Phase 3 study, to 36 months.
How is the FORTITUDE-3 trial progressing?
In June 2026, the Phase I/II FORTITUDE study reported encouraging results, showing reductions in biological markers linked to DUX4 activity and muscle damage. These findings are promising, but they do not yet demonstrate that del-brax slows disease progression or improves physical function.
However, given these encouraging results, the investigational treatment is now being evaluated in the Phase 3 FORTITUDE-3 trial, involving approximately 200 people with FSHD.
What did the data from the Phase 2 trial show?
Novartis showed the FDA that two endpoints measured in Phase 1 / 2 are showing promise. Plasma KHDC 1L, a marker that measures showing harmful DUX4 activity dropped by 50% in participants receiving del-brax, vs by 18% in those receiving the placebo. Another important biomarker, Creatine kinase, that shows muscle damage, dropped by 30% in those receiving del-brax vs 4% in the placebo group.
What endpoints are being measured in the Phase 3 trial?
The trial’s main measures (primary endpoints) assess muscle strength through Quantitative Muscle Testing (QMT) in the US, and walking/running ability through a timed 10-metre test in Europe.
Other measures (secondary endpoints) include mobility, physical function, fatigue, pain, sleep, quality of life, participants’ own assessments of their condition, and biological markers of disease activity.
While a trial only needs to measure one (primary) endpoint, measuring several (primary and secondary) makes the data more comprehensive and representative of how patients live with FSHD.
Together, what this trial measures aims to establish whether del-brax can make a meaningful difference to people living with FSHD.
Is the Phase 3 trial still enrolling participants?
At the moment, yes. FORTITUDE-3 is taking place at 46 sites worldwide, with many still recruiting participants aged 16–70, subject to certain eligibility criteria. There are currently 24 trials in Europe (including the UK). You can follow the development of the trial closely at ClinicalTrials.gov.
FSHD Europe’s perspective: staying cautiously optimistic
We welcome this progress and thank the people with FSHD who participate in clinical research. While we await evidence of clinical benefit, it is encouraging that this trial measures not only muscle strength, but also aspects of daily life that matter to our community.
We encourage individual patients and national organisations to learn about and engage with research on FSHD. Learn about it and explore taking part in a way that suits you.
We will continue to follow developments and share reliable updates as they become available with our community.
Are there any other Phase 3 trials taking place at the moment for FSHD?
No, not at present. FORTITUDE-3 is currently the only active Phase 3 treatment trial for FSHD worldwide, making its progress particularly newsworthy and important for the FSHD community.
Learn more
- Read the Community Update from Novartis to the FSHD Community
- For full details, view the webcast of Novartis’ 19 November 2026 investor presentation
- Learn more about why trials generally invite people in their country to participate
- Learn more about FSHD research, studies and trials, and how people living with FSHD can participate
